Journal of Bone and Joint Infection (Mar 2022)

Short and oral antimicrobial therapy for diabetic foot infection: a narrative review of current knowledge

  • S. M. Maurer,
  • Z. S. Hepp,
  • Z. S. Hepp,
  • S. McCallin,
  • F. W. A. Waibel,
  • F. C. Romero,
  • Y. Zorman,
  • B. A. Lipsky,
  • İ. Uçkay

DOI
https://doi.org/10.5194/jbji-7-61-2022
Journal volume & issue
Vol. 7
pp. 61 – 70

Abstract

Read online

Diabetic foot infection is a frequent complication in long-standing diabetes mellitus. For antimicrobial therapy of this infection, both the optimal duration and the route of administration are often based more on expert opinion than on published evidence. We reviewed the scientific literature, specifically seeking prospective trials, and aimed at addressing two clinical issues: (1) shortening the currently recommended antibiotic duration and (2) using oral (rather than parenteral) therapy, especially after the patient has undergone debridement and revascularization. We also reviewed some older key articles that are critical to our understanding of the treatment of these infections, particularly with respect to diabetic foot osteomyelitis. Our conclusion is that the maximum duration of antibiotic therapy for osteomyelitis should be no more than to 4–6 weeks and might even be shorter in selected cases. In the future, in addition to conducting randomized trials and propagating national and international guidance, we should also explore innovative strategies, such as intraosseous antibiotic agents and bacteriophages.